Comments
Expectations and blips in 2017
It’s 2017 and the medical devices industry starts off with discussions with the Centre on cardiac stents — the latter is keen to control the prices of these devices. The pharma industry expects to take a marginal WPI-linked price increase on medicines in the NLEM in the coming months. The industry projects growth this fiscal to close at 11 per cent, and FY18, at 12 per cent. A handful of Indian companies still have to resolve their issues with the USFDA. Clinical trials, combination drugs and drug price control litigation are scheduled for hearings at various courts and their outcomes will have vast impact.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.